arrow
K

Kjetil Boye

Oslo University Hospital
H指数:38
被引数:5,883

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

European guideline for imaging of primary paediatric and adult osteosarcoma and Ewing sarcoma: systematic review and joint statement by the FOSTER consortium, Euro Ewing Consortium, European Society of Paediatric Radiology, and the European Association of Nuclear Medicine

欧洲原发性儿童及成人骨肉瘤和尤因肉瘤影像学指南:FOSTER联盟、Euro Ewing联盟、欧洲儿科放射学会和欧洲核医学协会的系统综述与联合声明

2026-06-290
PRE
Biological Sample Collection to Advance Research and Treatment: A Fight Osteosarcoma Through European Research and Euro Ewing Consortium Statement
2024-06-131
OAAI
Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, doubleblind, placebo-controlled, phase 3 trial
LANCET
IF88.5
2024-06-013
PRE
The 1+Million Genomes Minimal Dataset for Cancer

癌症的100万个基因组最小数据集

2024-05-032
PRE
Systematic analysis of RNA-binding proteins identifies targetable therapeutic vulnerabilities in osteosarcoma

RNA结合蛋白的系统分析确定骨肉瘤中的可靶向治疗脆弱性

2024-04-010
OAAI
Ripretinib versus sunitinib in gastrointestinal stromal tumor: ctDNA biomarker analysis of the phase 3 INTRIGUE trial

瑞替尼与舒尼替尼治疗胃肠道间质瘤: 3期临床试验的ctDNA生物标志物分析

2024-01-0512
OAAI
Efficacy of immune checkpoint inhibitors in alveolar soft-part sarcoma: results from a retrospective worldwide registry
2023-12-016
OAAI
A systematic review of recent phase-II trials in refractory or recurrent osteosarcoma: Can we inform future trial design?

近期难治性或复发性骨肉瘤II期临床试验的系统综述: 我们能为未来的试验设计提供信息吗?

2023-11-015
OA
Patient-reported outcomes and tolerability in patients receiving ripretinib versus sunitinib after treatment with imatinib in INTRIGUE, a phase 3, open-label study1

在INTRIGUE中接受伊马替尼治疗后接受瑞替尼与舒尼替尼的患者报告的结局和耐受性,一项3期开放标签研究1

2023-10-014
OAAI